Cardiovascular risk factors, fitness and physical activity in rheumatic diseases

Current Opinion in Rheumatology

Volumn 19, Issue 2, 2007, Pages 190-196

  Turesson, Carl ^a,b   Matteson, Eric L ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MAYO CLINIC   (United States)

Author keywords

Cardiovascular disease; Physical activity; Rheumatoid arthritis; Risk factors; Systemic lupus erythematosus

Indexed keywords

CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DISABILITY; EXERCISE; FITNESS; FUNCTIONAL STATUS; HUMAN; INFLAMMATION; LIFESTYLE; LUPUS ERYTHEMATOSUS; MORBIDITY; MORTALITY; PHYSICAL ACTIVITY; POPULATION; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; EXERCISE; HUMANS; LIFE STYLE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOTOR ACTIVITY; PHYSICAL FITNESS; RISK FACTORS;

EID: 33846817044     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3280147107     Document Type: Review

References (69)

1. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48:54-58.
2. Doria A, Iaccardino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119:700-706. A recent update on long and short-term survival in SLE.
3. Jacobsson LT, Knowler WC, Pillemer S, et al. Rheumatoid arthritis and mortality: a longitudinal study in Pima Indians. Arthritis Rheum 1993; 36:1045-1053.
4. Manzi S, Meliahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145:408-415.
5. Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 2005; 17:286-292.
6. Minor MA, Lane NE. Recreational exercise in arthritis. Rheum Dis Clin North Am 1996; 22:563-577.
7. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44:2331-2337.
8. Chaves CJ. Stroke in patients with systemic lupus erythematosus and antiphospholipid antibody syndrome. Curr Treat Options Cardiovasc Med 2004; 6:223-229.
9. Wållberg-Jonsson S, Öhman M-L, Rantapää-Dahlqvist S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24:445-451.
10. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107:1303-1307.
11. Turesson C, Jarenros A, Jacobsson LT. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004; 63:952-955.
12. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993; 52:174-176.
13. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34:585-592.
14. Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I: Causes and risk of death. Arthritis Rheum 1997; 40:1868-1872.
15. Bond S, Farewell VT, Schentag CT, et al. Reporting of mortality in a psoriatic arthritis clinic is primarily a function of the number of clinic contacts and not disease severity. J Rheumatol 2005; 32:2364-2367.
16. Haara MM, Manninen P, Kroger H, et al. Osteoarthritis of finger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality. Ann Rheum Dis 2003; 62:151-158.
17. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30:1196-1202.
18. Jacobsson LT, Turesson C, Knowler WC, et al. Number of swollen joints predicts cardiovascular death: results from a population study of Pima Indians. Arthritis Rheum 2001; 44:1170-1176.
19. Frostegård J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005; 25:1776-1785.
20. Scherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2:99-106. An excellent review on the role of autoimmunity and inflammation in the pathogenesis of atherosclerosis.
21. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109:2818-2825.
22. Del Rincon I, Williams K, Stern MP, et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48:1833-1840.
23. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42:51-60.
24. Solomon DH, Curhan GC, Rimm EB, et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50:3444-3449.
25. Silman A, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis: results from a nationwide study of disease-discordant twins. Arthritis Rheum 1996; 39:732-735.
26. Bengtsson AA, Rylander L, Hagmar L, et al. Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden. Rheumatology (Oxford) 2002; 41:563-571.
27. Maradit-Kremers HM, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52:722-732. A long-term follow-up study of a well defined RA sample, in which disease-related and other risk factors for CVD are assessed.
28. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48:1530-1542.
29. Young A, Koduri G, Batley M, et al. Mortality in rheumatoid arthritis: increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2006; 14 August [Epub ahead of print]. A thorough study of a large early RA cohort, with assessment of mortality and predictors of overall and cause-specific mortality.
30. Jacobsson LT, Turesson C, Gülfe A, et al. Low incidence of first cardiovascular event in rheumatoid arthritis patients treated with TNF-blockers. J Rheumatol 2005; 32:1213-1218. Estimates the impact of anti-TNF treatment on the risk of CVD, and relates this to the extent of disability in a community-based sample of patients with RA.
31. Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extraarticular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 28 July [Epub ahead of print]. In this study of a large single-center sample of patients with severe extraarticular RA, the risk of coronary heart disease and other CVD events is estimated.
32. Liang KP, Liang KV, Matteson EL, et al. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extra-articular disease manifestations. Arthritis Rheum 2006; 54:642-648. The first large cohort study of noncardiac vascular disease in RA reveals an association between severe extraarticular manifestations and peripheral arterial disease and venous thromboembolic events.
33. Wållberg-Jonsson S, Johansson H, Öhman M-L, et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999; 26:2562-2571.
34. Goodson NJ, Symmons DPM, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52:2293-2299. A thorough study of a well defined inception cohort.
35. Björnedal L, Brand L, Klareskog L, Askling J. Impact of parental history on patients' cardiovascular mortality in rheumatoid arthritis. Ann Rheum Dis 2006; 65:741-745. The first large-scale study of the impact of family history on the risk of CVD in patients with RA.
36. Kremers HM, Nicola PJ, Crowson CS, et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004; 50:3450-3457.
37. Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165:1624-1629.
38. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982; 9:789-793.
39. Kumeda Y, Inaba M, Goto H, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46:1489-1497.
40. Toloza SM, Uribe AG, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII: Baseline predictors of vascular events. Arthritis Rheum 2004; 50:3947-3957.
41. Svenungsson E, Jensen-Urstad K, Heimbürger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104:1887-1893.
42. McEntegart A, Cappell H, Creran D, et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 2001; 40:640-644.
43. Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999; 26:1701-1704.
44. Divecha H, Sattar N, Rumley A, et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 2005; 109:171-176. This small but unique study provides a rare assessment of risk factors for CVD in ankylosing spondylitis.
45. Philbin EF, Ries MD, Groff GD, et al. Osteoarthritis as a determinant of an adverse coronary heart disease risk profile. J Cardiovasc Risk 1996; 3:529-533.
46. Hootman JM, Macera CA, Sam HA, et al. Physical activity levels among the general US adult population and in adults with and without arthritis. Arthritis Rheum 2003; 49:129-135.
47. Eurenius E, Stenström CH. Physical activity, physical fitness, and general health perception among individuals with rheumatoid arthritis. Arthritis Rheum 2005; 53:48-55. Self-reported physical activity, measured cardiorespiratory capacity and muscle function are reported in patients with early RA in this important study.
48. Wikström I, Isacsson Å, Jacobsson LT. Leisure activities in rheumatoid arthritis: change after disease onset and associated factors. Br J Occup Ther 2001; 64:87-92.
49. Wikström I, Book C, Jacobsson LT. Difficulties in performing leisure activities among persons with newly diagnosed rheumatoid arthritis: a prospective, controlled study. Rheumatology (Oxford) 2006; 45:1162-1166. Describes difficulties with leisure activities, including physical exercise, in an early RA inception cohort.
50. Wikström I, Jacobsson LT. Change in and predictors of leisure activities among patients with rheumatoid arthritis: a prospective study. Scand J Rheumatol 2005; 34:367-371.
51. Franco OH, de Laet C, Peeters A, et al. Effects of physical activity on life expectancy with cardiovascular disease. Arch Intern Med 2005; 165:2355-2360. Important observational data on the effects of exercise on morbidity and long-term survival.
52. Noda H, Iso H, Toyoshima H, et al. Walking and sports participation and mortality from coronary heart disease and stroke. J Am Coll Cardiol 2005; 46:1761-1767. In this well done observational study, the comparison of highly frequent exercise with moderate activity is a particular strength, since it avoids bias from comparison with secondary sedentary lifestyle.
53. Li TY, Rana JS, Manson JE, et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation 2006; 113:499-506. An important study that separates the effect of two related risk factors for CVD, and has implications for women with and without rheumatic diseases.
54. Vatten LJ, Nilsen TI, Holmen J. Combined effect of blood pressure and physical activity on cardiovascular mortality. J Hypertens 2006; 24:1939-1946. A well conducted, community-based study.
55. Sarna S, Kaprio J, Kujala UM, Koskenvuo M. Health status of former elite athletes: the Finnish experience. Aging (Milano) 1997; 9:35-41.
56. Swain DP, Franklin BA. Comparison of cardioprotective benefits of vigorous versus moderate intensity aerobic exercise. Am J Cardiol 2006; 97:141-147. A thorough and up-to-date review on the available evidence.
57. Albright C, Thompson DL. The effectiveness of walking in preventing cardiovascular disease in women: a review of the current literature. J Womens Health (Larchmt) 2006; 15:271-280. This review on low-intensity physical exercise in women has particular relevance for preventive interventions in patients with arthritis.
58. Lakka TA, Salonen JT. Moderate to high intensity conditioning leisure time physical activity and high cardiorespiratory fitness are associated with reduced plasma fibrinogen in eastern Finnish men. J Clin Epidemiol 1993; 46:1119-1127.
59. Eichner ER. Exercise and arthritis: the hematology of inactivity. Rheum Dis Clin North Am 1990; 16:815-825.
60. Warburton DE, Nicol CW, Bredin SS. Prescribing exercise as preventive therapy. CMAJ 2006; 174:961-974. Thoroughly reviews the methods and challenges of this field.
61. Gordon M-M, Thomson EA, Madhok R, Capell HA. Can intervention modify adverse lifestyle variables in a rheumatoid population? Results of a pilot study. Ann Rheum Dis 2002; 61:66-69.
62. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 2006; 54:226-229.
63. Boots JM, Christiaans MH, van Hoof JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004; 64:2047-2073.
64. Roman MJ, Schanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2399-2406.
65. Davis JM III, Maradit-Kremers H, Gabriel S. Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J Rheumatol 2005; 32:1856-1862.
66. Solomon DH. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum 2005; 52:1968-1978.
67. Solomon DH, Avorn J, Stürmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2006; 54:1378-1389. An important addition to the evidence in this area of major controversy.
68. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109:2068-2073.
69. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173-1177.